- Home
- ATRA vs CUE Comparison
ATRA vs CUE Comparison
Compare ATRA & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- CUE
- Stock Information
- Founded
- ATRA 2012
- CUE 2014
- Country
- ATRA United States
- CUE United States
- Employees
- ATRA N/A
- CUE N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- CUE Health Care
- Exchange
- ATRA Nasdaq
- CUE Nasdaq
- Market Cap
- ATRA 51.1M
- CUE 57.7M
- IPO Year
- ATRA 2014
- CUE 2018
- Fundamental
- Price
- ATRA $11.58
- CUE $0.88
- Analyst Decision
- ATRA Strong Buy
- CUE Strong Buy
- Analyst Count
- ATRA 4
- CUE 3
- Target Price
- ATRA $20.00
- CUE $3.00
- AVG Volume (30 Days)
- ATRA 57.7K
- CUE 553.7K
- Earning Date
- ATRA 08-11-2025
- CUE 08-13-2025
- Dividend Yield
- ATRA N/A
- CUE N/A
- EPS Growth
- ATRA N/A
- CUE N/A
- EPS
- ATRA N/A
- CUE N/A
- Revenue
- ATRA $199,732,000.00
- CUE $7,991,000.00
- Revenue This Year
- ATRA N/A
- CUE N/A
- Revenue Next Year
- ATRA N/A
- CUE $23.84
- P/E Ratio
- ATRA N/A
- CUE N/A
- Revenue Growth
- ATRA 475.53
- CUE 13.83
- 52 Week Low
- ATRA $5.01
- CUE $0.45
- 52 Week High
- ATRA $18.71
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- ATRA 66.87
- CUE 61.23
- Support Level
- ATRA $8.53
- CUE $0.84
- Resistance Level
- ATRA $13.46
- CUE $0.98
- Average True Range (ATR)
- ATRA 0.96
- CUE 0.10
- MACD
- ATRA 0.28
- CUE 0.01
- Stochastic Oscillator
- ATRA 62.65
- CUE 57.97
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.